Anavex Life Sciences Corp. (NASDAQ: AVXL) is one of 93 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Anavex Life Sciences Corp. to related businesses based off the strength of its earnings, risk, analyst recommendations, profitability, dividends, institutional ownership and valuation.
Valuation and Earnings
This table compares Anavex Life Sciences Corp. and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Anavex Life Sciences Corp.||N/A||-$15.61 million||-12.44|
|Anavex Life Sciences Corp. Competitors||$220.96 million||$56.99 million||-0.64|
Anavex Life Sciences Corp.’s competitors have higher revenue and earnings than Anavex Life Sciences Corp.. Anavex Life Sciences Corp. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently the more affordable than other companies in its industry.
This is a breakdown of current ratings for Anavex Life Sciences Corp. and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences Corp.||0||0||3||0||3.00|
|Anavex Life Sciences Corp. Competitors||161||542||1199||16||2.56|
Anavex Life Sciences Corp. presently has a consensus target price of $13.67, indicating a potential upside of 181.79%. All “Biotechnology” companies have a potential upside of 55.42%. Given Anavex Life Sciences Corp.’s stronger consensus rating and higher probable upside, research analysts plainly believe Anavex Life Sciences Corp. is more favorable than its competitors.
Volatility and Risk
Anavex Life Sciences Corp. has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp.’s competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
This table compares Anavex Life Sciences Corp. and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences Corp.||N/A||-95.68%||-84.88%|
|Anavex Life Sciences Corp. Competitors||-917.28%||-186.99%||-24.41%|
Insider and Institutional Ownership
24.4% of Anavex Life Sciences Corp. shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 11.6% of Anavex Life Sciences Corp. shares are owned by company insiders. Comparatively, 19.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.